B3-04: Gefitinib (IRESSA) versus vinorelbine in chemonaïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized Phase II study  by Crinò, Lucio et al.
Copyright © 2007 by the International Association for the Study of Lung Cancer S341
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
therapy regimen but without cetuximab. The choice of taxane was at 
the discretion of the investigator but had to be made before randomiza-
tion since on-study taxane (paclitaxel or docetaxel), ECOG PS (0 vs. 
1) and site were part of the stratiﬁcation scheme. The primary endpoint 
was progression-free-survival (PFS) as determined by an Independent 
Radiology Review Committee. In order to have 90% power to detect 
a hazard ratio of 0.75 of the combination arm over the control arm 
510 progression events were required. Secondary endpoints included 
response rate, time to response, duration of response, disease control 
rate, quality of life and overall survival (OS). 
Results and Conclusions: From December 2004 until October 2006 
676 patients were randomized at 97 centers in the US: 58.6% men, 41.4 
% women with a median age of 65 years (range 34-87). Data on the 
primary and secondary objectives along with unblinded safety data will 
be presented at the meeting.
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Background: This Phase II, open-label, parallel-group study (INVITE 
[IRESSA in NSCLC vs Vinorelbine Investigation in The Elderly]) 
compared geﬁtinib (IRESSA) with vinorelbine in chemonaïve elderly 
patients with locally advanced or metastatic non small-cell lung cancer.
Methods: Patients (≥70 years; performance status ≤2) were random-
ized to geﬁtinib (250 mg/day orally) or vinorelbine (30 mg/m2 infusion 
on Days 1 and 8 of a 21 day cycle). The primary endpoint was progres-
sion-free survival (PFS). Secondary endpoints were overall survival 
(OS), objective response rate (ORR; assessed by RECIST), quality 
of life (QoL; assessed by Functional Assessment of Cancer Therapy 
Lung [FACT-L] and improvement in the physical aspects of QoL as 
measured by the trial outcome index [TOI]), pulmonary symptom 
improvement (PSI; assessed by the 4 pulmonary items of the lung 
cancer symptoms subscale [LCS] of the FACT-L) and adverse event 
(AE) proﬁle. Exploratory analysis included EGFR gene copy number 
by ﬂuorescence in situ hybridization (FISH), EGFR protein expression 
and EGFR mutation analysis.
Results: 196 patients (75.5% male, 85.7% regular/ex smokers, 40.3% 
adenocarcinoma) from a total of 10 countries were randomized to 
geﬁtinib (n=97) or vinorelbine (n=99). Hazard ratios (HR) for PFS 
and OS were 1.19 (95% CI 0.85, 1.65) and 0.98 (95% CI 0.66, 1.47), 
respectively, for geﬁtinib vs vinorelbine. ORR and disease control rates 
were 3.1% and 43.3% (geﬁtinib) and 5.1% and 53.5% (vinorelbine), re-
spectively. FACT-L QoL improvement rates were higher with geﬁtinib 
vs vinorelbine (24.3% vs 10.9%, respectively) as was the TOI (22.9% 
vs 6.3%, respectively). Symptom improvement rates appeared similar 
with geﬁtinib vs vinorelbine: 36.6% vs 31.0% for PSI and 42.9% vs 
39.1% on the LCS. In the EGFR FISH-positive subgroup (n=54), HRs 
for geﬁtinib vs vinorelbine were 3.13 (95% CI 1.45, 6.76) for PFS and 
2.88 (95% CI 1.21, 6.83) for OS. In the EGFR FISH-negative subgroup 
(n=104), HRs for geﬁtinib vs vinorelbine were 0.93 (95% CI 0.59, 
1.46) for PFS and 0.79 (95% CI 0.46, 1.37) for OS. Few patients had 
tumor samples that were EGFR protein expression negative (13/157 
[8.3%] patients) or EGFR mutation-positive (7/65 [10.8%] patients), 
precluding further analysis of these data. The geﬁtinib arm had fewer 
treatment-related grade 3-5 AEs compared with vinorelbine (12.8% vs 
41.7%). The most common AEs were rash and diarrhea for geﬁtinib, 
and constipation, fatigue and neutropenia for vinorelbine. There were 
three treatment-related deaths in the vinorelbine arm, and none in the 
geﬁtinib arm.
Conclusions: Although the primary endpoint of demonstrating superior 
PFS for geﬁtinib relative to vinorelbine was not met, geﬁtinib was 
broadly similar to vinorelbine in terms of PFS, OS and ORR in this 
ﬁrst-line study in elderly patients. Geﬁtinib was better tolerated than 
vinorelbine. Overall QoL improvement, including TOI, was increased 
with geﬁtinib compared with vinorelbine, while PSI and LCS was 
similar in both arms. The difference between geﬁtinib and vinorelbine 
in the small exploratory analyses of FISH positive patients requires 
further investigation.
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Background: Meta-analyses based on data extracted from the literature 
rather than on individual patient data (IPD) must be interpreted with 
caution. We compare here results obtained with 3 sources: published 
data, study report data and IPD in analyzing randomized studies com-
paring docetaxel to vinca-alkaloïds in ﬁrst line treatment of NSCLC.
Material and Methods: Study search and selection have been previ-
ously described [Douillard JY et al. Proc ASCO 2006]. Summary sta-
tistics to perform a meta-analysis of published data were either directly 
extracted (hazard ratio (HR) and 95% CI available) or derived from 
the number of deaths and log-rank p value [Parmar M et al. Stat Med 
1998; 17: 2815-34]. Summary statistics of the study report data were 
either directly extracted, derived, or computed using life tables. All 
analyses were performed on an intention-to-treat basis when available. 
Logarithms of the HR were pooled by the inverse-variance weighting 
method. For IPD, the meta-analysis was performed by a log-rank test 
stratiﬁed for study.
